大环内酯类抗生素对从囊性纤维化患者中分离出的铜绿假单胞菌、洋葱伯克霍尔德菌、嗜麦芽窄食单胞菌和木糖氧化产碱菌的协同活性。
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
作者信息
Saiman Lisa, Chen Yunhua, Gabriel Pablo San, Knirsch Charles
机构信息
Department of Pediatrics, Columbia University, New York, New York 10032, USA.
出版信息
Antimicrob Agents Chemother. 2002 Apr;46(4):1105-7. doi: 10.1128/AAC.46.4.1105-1107.2002.
Abstract
Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.
摘要
阿奇霉素和克拉霉素与其他抗生素配对，以测试对从囊性纤维化（CF）患者中分离出的300种多重耐药病原体的协同活性。克拉霉素-妥布霉素对铜绿假单胞菌的活性最强，可抑制58%的菌株。阿奇霉素-甲氧苄啶-磺胺甲恶唑、阿奇霉素-头孢他啶以及阿奇霉素-强力霉素或阿奇霉素-甲氧苄啶-磺胺甲恶唑分别抑制嗜麦芽窄食单胞菌、洋葱伯克霍尔德菌复合体和木糖氧化无色杆菌（嗜碱假单胞菌）菌株的比例为40%、20%和22%。
相似文献
1
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Antimicrob Agents Chemother. 2002 Apr;46(4):1105-7. doi: 10.1128/AAC.46.4.1105-1107.2002.
2
Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.
Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44. doi: 10.1128/AAC.45.10.2838-2844.2001.
3
In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
J Med Microbiol. 2018 Sep;67(9):1217-1220. doi: 10.1099/jmm.0.000801. Epub 2018 Jul 17.
4
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
J Antimicrob Chemother. 2001 Oct;48(4):549-52. doi: 10.1093/jac/48.4.549.
5
Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
Transpl Infect Dis. 2018 Oct;20(5):e12955. doi: 10.1111/tid.12955. Epub 2018 Jun 25.
6
In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Antimicrob Agents Chemother. 2006 Feb;50(2):819-21. doi: 10.1128/AAC.50.2.819-821.2006.
7
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
J Clin Microbiol. 2001 Nov;39(11):3942-5. doi: 10.1128/JCM.39.11.3942-3945.2001.
8
Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.
Eur J Clin Microbiol Infect Dis. 1996 Nov;15(11):876-9. doi: 10.1007/BF01691221.
9
Comparative activity of antimicrobials against , and keratitis isolates.
Br J Ophthalmol. 2018 May;102(5):708-712. doi: 10.1136/bjophthalmol-2017-311751. Epub 2018 Feb 19.
10
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
J Glob Antimicrob Resist. 2018 Sep;14:224-227. doi: 10.1016/j.jgar.2018.03.002. Epub 2018 Mar 17.
引用本文的文献
1
Metagenomic evidence for a polymicrobial signature of sepsis.
Microb Genom. 2021 Sep;7(9). doi: 10.1099/mgen.0.000642.
2
Azithromycin and the microbiota of cystic fibrosis sputum.
BMC Microbiol. 2021 Mar 30;21(1):96. doi: 10.1186/s12866-021-02159-5.
3
Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.
Braz J Microbiol. 2021 Jun;52(2):597-606. doi: 10.1007/s42770-021-00433-2. Epub 2021 Jan 22.
4
Synergistic action of substituted indole derivatives and clinically used antibiotics against drug-resistant bacteria.
Future Microbiol. 2020 May;15(8):579-590. doi: 10.2217/fmb-2019-0094. Epub 2020 Jun 2.
5
Emergence of antibiotic resistance in intensive care unit; a critical review.
Genes Dis. 2019 Apr 17;6(2):109-119. doi: 10.1016/j.gendis.2019.04.001. eCollection 2019 Jun.
6
Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update.
Ann Clin Microbiol Antimicrob. 2019 Feb 4;18(1):7. doi: 10.1186/s12941-019-0306-0.
7
Synthesis and Biological Evaluation of Azamacrolide Comprising the Triazole Moiety as Quorum Sensing Inhibitors.
Molecules. 2018 May 4;23(5):1086. doi: 10.3390/molecules23051086.
8
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110. doi: 10.1080/14787210.2018.1425139. Epub 2018 Jan 16.
9
Influence of and on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.00096-16. Print 2017 Apr.
10
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
J Cyst Fibros. 2017 May;16(3):358-366. doi: 10.1016/j.jcf.2016.12.003. Epub 2016 Dec 24.
本文引用的文献
1
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
J Clin Microbiol. 2001 Nov;39(11):3942-5. doi: 10.1128/JCM.39.11.3942-3945.2001.
2
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
Infect Immun. 1999 Sep;67(9):4744-50. doi: 10.1128/IAI.67.9.4744-4750.1999.
3
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
J Clin Microbiol. 1999 Sep;37(9):2987-91. doi: 10.1128/JCM.37.9.2987-2991.1999.
4
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
N Engl J Med. 1999 Jan 7;340(1):23-30. doi: 10.1056/NEJM199901073400104.
5
Microbiology of sputum from patients at cystic fibrosis centers in the United States.
Clin Infect Dis. 1998 Jul;27(1):158-63. doi: 10.1086/514631.
6
Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1829-32. doi: 10.1164/ajrccm.157.6.9710075.
7
Anti-inflammatory activity of macrolides: a new therapeutic potential?
J Antimicrob Chemother. 1998 Mar;41 Suppl B:37-46. doi: 10.1093/jac/41.suppl_2.37.
8
Long-term azithromycin may improve lung function in children with cystic fibrosis.
Lancet. 1998 Feb 7;351(9100):420. doi: 10.1016/S0140-6736(05)78360-4.
9
Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa.
Acta Otolaryngol Suppl. 1996;525:56-60.
10
Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.
Antimicrob Agents Chemother. 1996 Oct;40(10):2271-5. doi: 10.1128/AAC.40.10.2271.
Zotero 插件